Genetically-modified animal models have been widely used in biomedical research and pharmaceutical R&D. Gene targeted mice, especially, are crucial for identifying gene function and deciphering disease mechanisms.
In 2018, GemPharmatech launched Knock-Out All Project (KOAP) to accelerate the delivery of cKO/KO mouse models. KOAP is aiming to generate cKO/KO strains for all 20,000 protein-coding genes in three years. Currently, GPT has successfully generated over 7,000 cKO/KO mouse models, covering genes in different research fields such as tumor, metabolism, immunity, development, DNA and protein modification. These strains can be directly ordered online (www.gempharmatech.com).
GPT also provided the fastest mouse cKO/KO service based on the advanced transgenic core and produced facility. In 2019, GPT has generated more than 5,000 cKO/KO strains.
GemPharmatech, currently operating both in China and United States, is a leading international company focused on mouse model development, production and marketing. With more than 600 employees, we are dedicated to provide the best service to the biomedical research community and pharmaceutical industries. GPT facility has been accredited by AAALAC since 2006.